Journal of Current Oncology

ORIGINAL ARTICLE
Year
: 2019  |  Volume : 2  |  Issue : 1  |  Page : 15--18

A retrospective case cohort analysis on the clinical utility of fosaprepitant in CINV prophylaxis in day care center of South India


Anita C Ramesh1, Sagar B Bhagat2 
1 Department of Medical Oncology, HCG Cancer Centre, Chennai, Tamil Nadu, India
2 Department of Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, Maharashtra, India

Correspondence Address:
Dr. Sagar B Bhagat
Glenmark Pharmaceuticals Limited, Mumbai 400099, Maharashtra
India

Background: Control of chemotherapy-induced nausea and vomiting is a crucial factor in ensuring patient’s compliance and adherence to cancer chemotherapy cycle. Fosaprepitant is a water-soluble N-phosphoryl derivative of aprepitant, which is often administered along with 5-hydroxytryptamine 3 antagonist and a steroid in patients with highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). Materials and Methods: A single-centric, retrospective cohort study was conducted in HCG Cancer Centre in South India, where patients who were prescribed fosaprepitant as a part of standard therapy were enrolled. Results: Among the 290 patients who were included in the analysis, 41.72% were male, 58.27% were female, and 36.20% belonged to 51–60 years of age. Advanced breast carcinoma was the most common diagnosis in 38.96% patients. HEC was prescribed in 222 patients; moderate emetogenic drugs and regimen were prescribed in 62 patients. Among patients who were prescribed HEC and MEC drugs and regimen, fosaprepitant, palonosetron, and dexamethasone were prescribed on day 1 followed by dexamethasone on days 2, 3, and 4. No infusion site reaction, hiccups, or any other adverse reactions were noted. Complete response was noted in all patients (100%) with HEC and MEC regimen cases. The formulation was well tolerated with none reporting any persistent or delayed or breakthrough emesis. Conclusion: Single-dose fosaprepitant used in combination with palonosetron and dexamethasone was well tolerated and effective in preventing chemotherapy-induced vomiting in patients receiving highly and moderately emetogenic drugs and regimen.


How to cite this article:
Ramesh AC, Bhagat SB. A retrospective case cohort analysis on the clinical utility of fosaprepitant in CINV prophylaxis in day care center of South India.J Curr Oncol 2019;2:15-18


How to cite this URL:
Ramesh AC, Bhagat SB. A retrospective case cohort analysis on the clinical utility of fosaprepitant in CINV prophylaxis in day care center of South India. J Curr Oncol [serial online] 2019 [cited 2024 Mar 28 ];2:15-18
Available from: http://www.https://journalofcurrentoncology.org//article.asp?issn=2589-8892;year=2019;volume=2;issue=1;spage=15;epage=18;aulast=Ramesh;type=0